Avalo Therapeutics AVTX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's accounts payable?
- Avalo Therapeutics (AVTX) reported accounts payable of $356K in Q1 2026.
- How has Avalo Therapeutics's accounts payable changed year-over-year?
- Avalo Therapeutics's accounts payable decreased by 47.7% year-over-year, from $681K to $356K.
- What is the long-term trend for Avalo Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Avalo Therapeutics's accounts payable has grown at a -44.4% compound annual growth rate (CAGR), from $2.57M to $137K.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.